Merck Beats Estimates in Q2 Earnings Call

Merck's Q2 earnings call revealed continued sales growth driven by its oncology portfolio and new product launches. The company reported revenue of $16.61 billion, exceeding analyst estimates by 5.1%, with a year-over-year growth rate of 4% in constant currency.

CFO Caroline Litchfield highlighted the strong commercial and operational execution that continues to drive near-term performance while investing in the pipeline.

Management acknowledged the impact of higher operating expenses, including acquisition-related charges, on overall profitability. The company slightly lifted its revenue guidance for the full year to $66.8 billion at the midpoint from $66.4 billion but lowered its Adjusted EPS guidance to $2.71 at the midpoint, a 46.9% decrease.

Analysts' questions during the call highlighted topics such as the potential for broad sac-TMT plus pembrolizumab trials in first-line lung cancer and the expected pace of LIPFENDRA's commercial adoption.